Table 3 Follow-up and long-term complications
Parameters | Control (n = 142) | Observation (n = 128) | All (n = 270) | P |
|---|---|---|---|---|
Follow-up | Â | Â | Â | 0.181 |
 Yes | 112 (78.87%) | 109 (85.16%) | 221 (81.85%) |  |
 No | 30 (21.13%) | 19 (14.84%) | 49 (18.15%) |  |
Follow-up period, month | 97.54 ± 25.42 | 101.87 ± 33.81 | 99.67 ± 29.87 | 0.229 |
Long-term complications | ||||
 Upper abdominal discomfort | 15 (13.64%) | 19 (17.43%) | 34 (15.53%) | 0.438 |
 Bloating | 14 (12.73%) | 17 (15.60%) | 31 (14.16%) | 0.543 |
 Cholangitis | 36 (32.73%) | 9 (8.26%) | 45 (20.55%) |  < 0.001 |
 Occasional cholangitis | 15 (13.64%) | 5 (4.59%) | 20 (9.13%) | 0.020 |
 More severe cholangitis | 1 (0.91%) | 1 (0.92%) | 2 (0.91%) | 1.000 |
 Bile duct stones | 36 (32.73%) | 6 (5.50%) | 42 (19.18%) |  < 0.001 |
 Cholangiocarcinoma | 3 (2.73%) | 2 (1.83%) | 5 (2.28%) | 1.000 |
 Stricture | 1 (0.91%) | 2 (1.83%) | 3 (1.37%) | 0.622 |
 Diarrhoea | 0 (0.00%) | 1 (0.92%) | 1 (0.46%) | 0.498 |